Skip to main content
Fig. 7 | Cancer Cell International

Fig. 7

From: LncRNA LBX2-AS1 promotes colorectal cancer progression and 5-fluorouracil resistance

Fig. 7

Low LBX2-AS1 expression in CRC correlates with patient benefit from 5-FU therapy. A Kaplan–Meier analysis showing the overall survival of patients between the high and LBX2-AS1-low expressing groups from cohort C. B, C PDXs with LBX2-AS1-high and LBX2-AS1-low expression were treated with 5-FU (30 mg/kg body weight) or vehicle for 28 days. Xenografted tumor growth was monitored, and the tumor growth rates were calculated. D Working model illustrating how LBX2-AS1-enhances CRC cell malignant phenotypes and promotes 5-FU resistance. For A, log rank test, B and C, *P < 0.05; #P > 0.05, Student’s t-test

Back to article page